Title: PSMA Addition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care, alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
- Principal Investigator: Dr. Medhat Osman
- Study Coordinator: Lindsey Vargo
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study.
This study is administered by VREF and funded by Novartis.
Find Out More
This study is currently enrolling participants. To learn more about PSMA Additon and how you can join contact our research office at (314) 289-7690.
If you are a veteran receiving care through the VA St. Louis Health Care System and believe you may be eligible for this study, please speak with your Physician. For general information about our research, please visit our main Clinical Trials page or contact us directly.